Navigation Links
Landsec and Spartan Bioscience Trial the World’s First On-Site Legionella DNA Test in the UK
Date:5/7/2019

Landsec and Spartan Bioscience today announced they will trial the world’s first on-site Legionella DNA test in the UK.

In May, Landsec will undertake trials using Spartan’s innovative Legionella test. Spartan’s test provides highly accurate qPCR Legionella results in 45 minutes, enabling operators to take corrective action within hours instead of weeks. This test, if approved, could replace the need to send samples to laboratories and ensure enhanced levels of water safety.

Spartan’s Legionella test is widely used by North America’s leading real estate companies, data facilities, and healthcare organizations. In addition, it is validated according to ISO/Technical Standard 12869:2012. Landsec is the first company to trial Spartan’s technology in the UK.

Legionella is a common bacterium that can infect the water systems of large buildings. When infected water systems release aerosolized water droplets contaminated with Legionella, building occupants can breathe in the contaminated air and contract Legionnaires’ disease, a potentially fatal pneumonia. There are dozens of high-profile Legionnaires’ disease outbreaks in the UK each year.(1) For example, in August 2017, a woman died from a Legionella outbreak that was traced back to a contaminated water system in a Ludlow hotel.(2)

The traditional Legionella testing method, bacterial culture, takes 10-14 days to provide results. But this turnaround time can be too slow because Legionella can grow to outbreak levels in as few as 7 days.(3) In comparison, Spartan’s test provides results in 45 minutes. Additionally, Spartan’s Legionella test uses a Nobel-Prize winning chemistry called quantitative Polymerase Chain Reaction (qPCR). qPCR is commonly used for medical diagnostics because of its highly-improved accuracy compared to traditional testing methods.

“Landsec is always looking for innovative solutions that can make our buildings and their occupants safer,” said Tim Peacock, Innovation Director at Landsec. “We look forward to working with Spartan to bring this technology to the UK and investigating methods to further reduce the risk of Legionnaires’ outbreaks in our buildings.”

“Landsec is one of the leading property management companies in the UK and we are excited to have them onboard with this trial. With support from businesses like Landsec, we hope to eventually eradicate Legionnaires’ outbreaks around the world,” said Paul Lem, M.D., CEO of Spartan Bioscience.

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing.(5) Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. The Spartan Cube, the world’s smallest DNA analyzer, enables unprecedented portability and convenience in applications such as infectious disease, pharmacogenetics, and food and water safety testing. Spartan created the first on-site Legionella DNA test to reduce the risk of Legionnaires’ disease outbreaks in buildings. It consists of a coffee-cup-sized, portable DNA analyzer called the Spartan Cube® and a single-use disposable test cartridge. https://www.spartanbio.com/

About Landsec
Landsec is one of the largest commercial property development and real estate investment companies in the United Kingdom, with more than 23M sq. ft. and £14B under management. Landsec’s portfolio includes landmark buildings such as Piccadilly Lights and the Zig Zag Building. Landsec is highly committed to improving health and safety through innovation solutions.

References
1. Public Health England. (2018). Legionnaires disease in residents of England and Wales–2016.
2. BBC. (2017). Fatal Legionnaires' outbreak at Ludlow hotel. September 13.
3. Marshall AG, Bellucci EC. (1986). Hospitality Review. 1(4): Article 2.
4. Ahmed S et al. (2019). Journal of Water and Health. 17(2): 237–253.
5. Roberts JD et al. (2012). Lancet. 379:1705–11.

Read the full story at https://www.prweb.com/releases/landsec_and_spartan_bioscience_trial_the_worlds_first_on_site_legionella_dna_test_in_the_uk/prweb16287711.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Indivumed Partners with Flagship Biosciences to Provide Global Tissue-Based Diagnostics Services
2. SeqOnce Biosciences Launches RhinoSeq™ Rapid DNA Library Preparation Kit
3. StressMarq Biosciences Inc. PCT Patent Application for a Novel Antibody Therapeutic Candidate to Combat Parkinson’s Disease is Published
4. Fluxion Biosciences Receives National Cancer Institute Grant for Development of ERASE-Seq Liquid Biopsy Technology
5. ACEA Biosciences Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery
6. Tosoh Bioscience LLC invests in Semba Biosciences
7. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
8. ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.
9. ACEA Biosciences Introduces an Exploratory xCELLigence® RTCA S16 Instrument
10. Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
11. New bilateral pilot opportunity will fund collaborations between US and UK bioscience researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/4/2019)... ... 04, 2019 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... of $31M, up 12% from Q1-18. The growth is associated with uptick in ... excellence initiatives worldwide. , Laurent Pruvost , President & CEO of In'Tech ...
(Date:6/4/2019)... ... June 04, 2019 , ... ... for salient features of seizure risk signals, usually based on variations of amplitude, ... remains the only acceptable diagnostic methodology due to the complexity and variability of ...
(Date:6/1/2019)... ... May 31, 2019 , ... The ... Rosati recently invested in BioFactura’s $6M Series B Financing Round. , “With ... institutional investors who bring significant financial and business resources to bear as we ...
Breaking Biology News(10 mins):
(Date:6/12/2019)... N.J. (PRWEB) , ... June 12, 2019 , ... ... custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and ... Shanghai Zillion has been signed. The agreement will grant exclusive rights for Zillion ...
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, the ... national leader in opioid treatment, announced today they are partnering to combat the ... recently deployed its virtual care platform at the Mayo Clinic to drive shared ...
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation and ... led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, which ... The CAR enables the final product to produce chemicals in the hopes that the ...
(Date:5/31/2019)... ... May 30, 2019 , ... A study released ... delivery system for the sustained release of human placental stem cell (HPSC)-derived conditioned ... able to deliver CM into the injured kidney, where it helped restore function ...
Breaking Biology Technology: